Literature DB >> 11815472

Lipotoxicity in human pancreatic islets and the protective effect of metformin.

Roberto Lupi1, Silvia Del Guerra, Vanna Fierabracci, Lorella Marselli, Michela Novelli, Giovanni Patanè, Ugo Boggi, Franco Mosca, Salvatore Piro, Stefano Del Prato, Piero Marchetti.   

Abstract

Human pancreatic islets from eight donors were incubated for 48 h in the presence of 2.0 mmol/l free fatty acid (FFA) (oleate to palmitate, 2 to 1). Insulin secretion was then assessed in response to glucose (16.7 mmol/l), arginine (20 mmol/l), and glyburide (200 micromol/l) during static incubation or by perifusion. Glucose oxidation and utilization and intra-islet triglyceride content were measured. The effect of metformin (2.4 microg/ml) was studied because it protects rat islets from lipotoxicity. Glucose-stimulated but not arginine- or glyburide-stimulated insulin release was significantly lower from FFA-exposed islets. Impairment of insulin secretion after exposure to FFAs was mainly accounted for by defective early-phase release. In control islets, increasing glucose concentration was associated with an increase in glucose utilization and oxidation. FFA incubation reduced both glucose utilization and oxidation at maximal glucose concentration. Islet triglyceride content increased significantly after FFA exposure. Addition of metformin to high-FFA media prevented impairment in glucose-mediated insulin release, decline of first-phase insulin secretion, and reduction of glucose utilization and oxidation without significantly affecting islet triglyceride accumulation. These results show that lipotoxicity in human islets is characterized by selective loss of glucose responsiveness and impaired glucose metabolism, with a clear defect in early-phase insulin release. Metformin prevents these deleterious effects, supporting a direct protective action on human beta-cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11815472     DOI: 10.2337/diabetes.51.2007.s134

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  47 in total

1.  Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes.

Authors:  Valeriya Lyssenko; Roberto Lupi; Piero Marchetti; Silvia Del Guerra; Marju Orho-Melander; Peter Almgren; Marketa Sjögren; Charlotte Ling; Karl-Fredrik Eriksson; Asa-Linda Lethagen; Rita Mancarella; Göran Berglund; Tiinamaija Tuomi; Peter Nilsson; Stefano Del Prato; Leif Groop
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

Review 2.  Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus.

Authors:  Helmut Walter; Georg Lübben
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Effects of metformin on oxidative stress, adenine nucleotides balance, and glucose-induced insulin release impaired by chronic free fatty acids exposure in rat pancreatic islets.

Authors:  S Piro; A M Rabuazzo; M Renis; F Purrello
Journal:  J Endocrinol Invest       Date:  2011-07-12       Impact factor: 4.256

Review 4.  Small-molecule inhibition of inflammatory β-cell death.

Authors:  M Lundh; S S Scully; T Mandrup-Poulsen; B K Wagner
Journal:  Diabetes Obes Metab       Date:  2013-09       Impact factor: 6.577

5.  The p66(Shc) redox adaptor protein is induced by saturated fatty acids and mediates lipotoxicity-induced apoptosis in pancreatic beta cells.

Authors:  Annalisa Natalicchio; Federica Tortosa; Rossella Labarbuta; Giuseppina Biondi; Nicola Marrano; Emanuele Carchia; Anna Leonardini; Angelo Cignarelli; Marco Bugliani; Piero Marchetti; Gian Paolo Fadini; Marco Giorgio; Angelo Avogaro; Sebastio Perrini; Luigi Laviola; Francesco Giorgino
Journal:  Diabetologia       Date:  2015-03-26       Impact factor: 10.122

Review 6.  AMP-activated protein kinase and metabolic control.

Authors:  Benoit Viollet; Fabrizio Andreelli
Journal:  Handb Exp Pharmacol       Date:  2011

7.  Pioglitazone/metformin.

Authors:  Emma D Deeks; Lesley J Scott
Journal:  Drugs       Date:  2006       Impact factor: 9.546

8.  Stevioside Counteracts Beta-Cell Lipotoxicity without Affecting Acetyl CoA Carboxylase.

Authors:  Jianguo Chen; Per Bendix Jeppesen; Iver Nordentoft; Kjeld Hermansen
Journal:  Rev Diabet Stud       Date:  2007-02-10

Review 9.  Interventions to preserve beta-cell function in the management and prevention of type 2 diabetes.

Authors:  Kathleen A Page; Tamar Reisman
Journal:  Curr Diab Rep       Date:  2013-04       Impact factor: 4.810

Review 10.  Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control.

Authors:  Piero Marchetti; Roberto Lupi; Silvia Del Guerra; Marco Bugliani; Valentina D'Aleo; Margherita Occhipinti; Ugo Boggi; Lorella Marselli; Matilde Masini
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.